Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Ragini Kudchadkar

Medical Oncology Atlanta, GA Medical Doctor

NPI 1982750667 CMS profile 44889

1365 Clifton Rd Ne, 2Nd Floor, Atlanta, GA 30322

Open in the dashboard

General payments

$69,245

59 records reported · program years 2019–2023

Research payments

$2,188

Paid to them · 8 records reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,906,027 paid to institutions, not to them · program years 2019–2024

Through program year 2023, Ragini Kudchadkar of Atlanta, GA is reported in the CMS Open Payments database as having received $69,245 across 59 general payments and $2,188 in research payments paid to them. Separately, studies naming them as principal investigator received $1,906,027 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2023 Research $251 3
2022 General $10,314 11
2022 Research $1,937 5
2021 General $16,181 8
2020 General $9,853 4
2019 General $32,898 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ragini Kudchadkar
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Ragini Kudchadkar were reported at $0. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Ragini Kudchadkar Medical Oncology median Middle half National median
2019 $32,898 $968 $140–$6,658 $163
2020 $9,853 $747 $102–$5,891 $114
2021 $16,181 $430 $50–$4,098 $132
2022 $10,314 $812 $127–$4,907 $149
2023 $0 $957 $144–$5,248 $160
2024 $0 $1,042 $149–$5,650 $164
2025 $0 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Genzyme Corporation $18,147 10 payments
  2. Novartis Pharmaceuticals Corporation $14,969 8 payments
  3. Merck Sharp & Dohme Corporation $14,542 23 payments
  4. E.R. Squibb & Sons, L.L.C. $8,185 11 payments
  5. Array BioPharma Inc. $6,600 4 payments
  6. Regeneron Pharmaceuticals, Inc. $2,948 1 payment
  7. Genentech USA, Inc. $1,980 1 payment
  8. Eisai Inc. $1,875 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Consulting Fee $57,217 16 payments
  2. Honoraria $4,375 2 payments
  3. Travel and Lodging $3,880 15 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,100 1 payment
  5. Food and Beverage $1,673 25 payments
Products named General payments · program years 2019–2023
  1. TAFINLAR $14,969 8 payments
  2. MEKINIST $14,969 8 payments
  3. LIBTAYO Oncology $13,832 9 payments
  4. BRAFTOVI Oncology $4,375 2 payments
  5. OPDIVO $3,360 3 payments
  6. KEYTRUDA $3,182 18 payments
  7. LIBTAYO Oncology $2,948 1 payment
  8. Braftovi Melanoma $2,225 2 payments
  9. Mektovi $2,225 2 payments
  10. Erivedge $1,980 1 payment
  11. Other $1,875 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2023
  1. F. Hoffmann-La Roche AG $1,350 1 payment
  2. Regeneron Pharmaceuticals, Inc. $838 7 payments

Records

67 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record